Newamsterdam Pharma Company N.V. ( (NAMS) ) has released its Q1 earnings. Here is a breakdown of the information Newamsterdam Pharma Company N.V. presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company based in the Netherlands, focusing on developing therapies for cardiometabolic diseases, with a primary emphasis on their CETP inhibitor, obicetrapib, aimed at lowering LDL-C levels in patients where current treatments are inadequate.